SEARCH

SEARCH BY CITATION

The Journal of the CardioMetabolic Syndrome (JCMS ) launches at a critical juncture in the world of metabolism, given ongoing controversies about the exact nature and existence of the “metabolic syndrome.” We do not wish to engage in these arguments for or against the precise definition of this syndrome. Just as the terms “diabetes” and “prediabetes” are terminology designed to express a disease state, or a disease risk constellation, the term “metabolic syndrome” also attempts such a description. Hopefully, the term “cardiometabolic” describes the intricate connections among cardiovascular and metabolic abnormalities that predispose to cardiovascular disease—the leading cause of mortality in the Western world.

JCMS will attempt to connect the litany of organ system abnormalities that cluster together and predispose to premature cardiovascular, renal, and cerebrovascular morbidity and mortality. The cardiometabolic syndrome (CMS) and diabetes are growing dramatically, with recent estimates that there are 29 million people with diabetes (21 million diagnosed and 8 million who have yet to be diagnosed) and 42 million people with the CMS.1 The number with the syndrome is arguably much higher, since over half of the 65 million people with hypertension are thought to have the CMS. Thus, those organizations that are worried about “territorial issues” need not be concerned, as there are sufficient areas for all interested to explore and elucidate. In fact, the American Heart Association, the American Diabetes Association, the American Society of Clinical Endocrinology, the American Society of Nephrology, and others should consider striving for coordination of all of their individual efforts. After all, we are all trying to be diligent on behalf of the patients who have these coexisting risks for heart disease, stroke, and chronic kidney disease. Let's get the organizations outside of their silos and integrate our efforts to deal with this growing public health problem.

In launching JCMS , the Editor in Chief and the Editorial Board will attempt to consolidate disparate information and provide all interested health care professionals with the most recent developments on various aspects of the CMS. We will endeavor to address the various organ system pathophysiologies involved, with the concurrent goal of providing information on therapeutic developments in the area. JCMS is a peer-reviewed clinical outreach journal circulated to 25,000 physicians, including endocrinologists, cardiologists, family practitioners, and diabetologists—the large circulation will engage a vital cross-section of clinicians. JCMS was created and is published by Le Jacq Ltd., a leading publisher of clinical outreach journals including The Journal of Clinical Hypertension, Congestive Heart Failure, The American Journal of Geriatric Cardiology, Preventive Cardiology, The American Heart Hospital Journal , and others.

In the first issue, we have recruited experts—many on our Editorial Board—to review most of the organ systems that are part and parcel of the CMS. Hayden and Sowers launch the issue with an overview of organ involvement; seven review articles follow, exploring in depth the effects of the syndrome on the kidney, liver, heart, skeletal muscle, fat, bone, and islet abnormalities, and the effects of renin—angiotensin system blockade in the management of obesity-related hypertension. Original studies by O'Malley et al. and Ostfeld et al. share new findings on, respectively, case management impact on cardiovascular risk factors and the use of elevated triglyceride/high-density lipoprotein ratios as markers for the increased burden of coronary artery disease on cardiac catheterization. Szmitko and Verma review C-reactive protein, analyzing its usefulness in the clinical setting as a guide to identifying patients with, or at risk of developing, diabetes and the CMS. CME credit is available for readers who review these findings and respond to the questions that follow the article. Regular departments covering a variety of aspects of the CMS will appear in each issue. The premiere issue includes a case report of a rare occurrence of calciphylaxis in the CMS, a discussion of antihypertensive medications and diabetes for the clinician, and an insightful column on the value of tissue Doppler imaging of diastolic heart failure in an obese patient with the CMS.

In future issues, we plan to devote more space to original research in the CMS arena. As the Editor in Chief, I am delighted that we could assemble such an august group of experts to serve on the Editorial Board. We who serve on the Editorial Board believe that the JCMS will be a valuable and practical journal for health care professionals caring for complex patients presenting with multiple cardiovascular risk factors.

Reference

  1. Top of page
  2. Reference
  • 1
    Kleinfeld NR. Diabetes and its awful toll quietly emerge as a crisis. New York Times. January 9, 2006:A1, A18A19.